Structure activity relationships of 5-HT

Adenosine Serotonin Serotonin Antagonists Structure-Activity Relationship Receptors, Purinergic P1 Receptor, Serotonin, 5-HT2B
Adenosine receptor Functional antagonism G protein-coupled receptor Methanocarba Nucleosides Radioligand binding Scaffold repurposing Serotonin 5-HT(2B) receptor Serotonin receptor Structure activity relationship

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Nov 2023
Historique:
received: 04 04 2023
revised: 17 07 2023
accepted: 27 07 2023
pmc-release: 05 11 2024
medline: 22 8 2023
pubmed: 11 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

(N)-Methanocarba adenosine derivatives were structurally modified to target 5-HT

Identifiants

DOI: 10.1016/j.ejmech.2023.115691 PMID: 37562117 PMC: PMC10529765
pubmed: 37562117
pii: S0223-5234(23)00657-8
doi: 10.1016/j.ejmech.2023.115691
pmc: PMC10529765
mid: NIHMS1924271
pii:
doi:

Substances chimiques

Adenosine K72T3FS567
Serotonin 333DO1RDJY
Serotonin Antagonists 0
Receptors, Purinergic P1 0
Receptor, Serotonin, 5-HT2B 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115691

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM133421
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA DK031117
Pays : United States

Informations de copyright

Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Annu Rep Med Chem. 2021;57:49-107
pubmed: 34744210
Br J Pharmacol. 1999 Jul;127(5):1075-82
pubmed: 10455251
Mol Pharmacol. 2009 Oct;76(4):710-22
pubmed: 19570945
Front Cell Neurosci. 2019 Mar 28;13:124
pubmed: 30983976
J Med Chem. 2005 Dec 29;48(26):8103-7
pubmed: 16366590
Bioorg Med Chem Lett. 2020 Nov 1;30(21):127511
pubmed: 32853682
Science. 2013 May 3;340(6132):615-9
pubmed: 23519215
Drug Dev Res. 2015 Jan 25;76(1):31-39
pubmed: 25620128
J Med Chem. 2016 Dec 22;59(24):11006-11026
pubmed: 27933810
Acta Physiol Scand. 2004 Oct;182(2):133-43
pubmed: 15450109
Pharmaceuticals (Basel). 2021 Jan 20;14(2):
pubmed: 33498477
J Am Heart Assoc. 2018 Jan 30;7(3):
pubmed: 29382665
Neuroscience. 2015 Jan 29;285:312-23
pubmed: 25451280
Nat Med. 2011 Nov 27;17(12):1668-73
pubmed: 22120177
Assay Drug Dev Technol. 2023 Apr;21(3):89-96
pubmed: 36930852
Purinergic Signal. 2015 Sep;11(3):371-87
pubmed: 26111639
J Pharmacol Toxicol Methods. 2001 Sep-Oct;46(2):61-71
pubmed: 12481843
ACS Med Chem Lett. 2020 Feb 14;11(10):1935-1941
pubmed: 33062176
Psychopharmacology (Berl). 2017 May;234(9-10):1395-1418
pubmed: 28265714
J Med Chem. 2000 Jun 1;43(11):2196-203
pubmed: 10841798
J Med Chem. 1996 Sep 13;39(19):3739-47
pubmed: 8809162
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Int J Mol Sci. 2020 Dec 20;21(24):
pubmed: 33419260
Cell Rep. 2023 Mar 28;42(3):112203
pubmed: 36884348
Curr Pharm Des. 2012;18(9):1292-310
pubmed: 22316157
Am J Pathol. 2018 May;188(5):1113-1119
pubmed: 29454752
Int J Mol Sci. 2020 Dec 28;22(1):
pubmed: 33379351
Science. 2013 Dec 20;342(6165):1521-4
pubmed: 24357322
J Med Chem. 1991 Sep;34(9):2877-82
pubmed: 1895305
Nature. 2012 Dec 13;492(7428):215-20
pubmed: 23235874
Eur J Med Chem. 2022 Mar 5;231:114103
pubmed: 35152062
PLoS One. 2020 Nov 25;15(11):e0238407
pubmed: 33237915
ACS Omega. 2018 Oct 31;3(10):12658-12678
pubmed: 30411015
Bioorg Med Chem. 2004 Jun 1;12(11):2995-3007
pubmed: 15142558
J Med Chem. 2017 Apr 13;60(7):3109-3123
pubmed: 28319392
Antiviral Res. 2006 Sep;71(2-3):268-75
pubmed: 16730077
RSC Med Chem. 2021 Jul 13;12(11):1808-1825
pubmed: 34825182
J Med Chem. 2002 Jan 17;45(2):420-9
pubmed: 11784146
J Med Chem. 2002 Jan 3;45(1):208-18
pubmed: 11754592
Circulation. 2021 Mar 30;143(13):1317-1330
pubmed: 33474971
J Med Chem. 2019 Feb 14;62(3):1502-1522
pubmed: 30605331
Nat Struct Mol Biol. 2018 Sep;25(9):787-796
pubmed: 30127358
Bioorg Med Chem Lett. 2020 Dec 1;30(23):127599
pubmed: 33031923
J Med Chem. 2012 Sep 27;55(18):8075-90
pubmed: 22921089
Neuropsychopharmacology. 2020 Nov;45(12):2098-2105
pubmed: 32473594
PLoS One. 2008 May 07;3(5):e2107
pubmed: 18461129
Front Pharmacol. 2023 Jan 24;14:1101290
pubmed: 36762110

Auteurs

Dilip K Tosh (DK)

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

Maggie M Calkins (MM)

Medical College of Wisconsin, Department of Cell Biology, Neurobiology, and Anatomy, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.

Marko S Ivancich (MS)

Medical College of Wisconsin, Department of Cell Biology, Neurobiology, and Anatomy, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.

Hailey A Bock (HA)

Medical College of Wisconsin, Department of Cell Biology, Neurobiology, and Anatomy, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.

Ryan G Campbell (RG)

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

Sarah A Lewicki (SA)

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

Eric Chen (E)

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

Zhan-Guo Gao (ZG)

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

John D McCorvy (JD)

Medical College of Wisconsin, Department of Cell Biology, Neurobiology, and Anatomy, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.

Kenneth A Jacobson (KA)

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: kennethj@niddk.nih.gov.

Articles similaires

The periaxonal space as a conduit for cerebrospinal fluid flow to peripheral organs.

Xinyu Li, Siman Wang, Dianjun Zhang et al.
1.00
Cerebrospinal Fluid Animals Liver Glymphatic System Spinal Cord

Impact of Vitamin D deficiency on immunological and metabolic responses in women with recurrent pregnancy loss: focus on VDBP/HLA-G1/CTLA-4/ENTPD1/adenosine-fetal-maternal conflict crosstalk.

Aisha Nawaf Al Balawi, Noaf Abdullah N Alblwi, Riham Soliman et al.
1.00
Humans Female Pregnancy Abortion, Habitual Adult

Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-

Alonzo González-González, Oscar Sánchez-Sánchez, Lilián Yépez-Mulia et al.
1.00
Giardia lamblia Trichomonas vaginalis Entamoeba histolytica Antiprotozoal Agents Quinoxalines

The association of gene polymorphisms of adenosine and dopamine receptors with the response to caffeine citrate treatment in infants with apnea of prematurity: a prospective nested case-control study.

Jiangbiao Xie, Wei Zhuang, Yao Zhu et al.
1.00
Humans Caffeine Infant, Newborn Prospective Studies Female

Classifications MeSH

questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Adénosine › Structure activity relationships of 5-HT
questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Autacoïdes › Sérotonine › Structure activity relationships of 5-HT
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents sérotoninergiques › Antisérotonines › Structure activity relationships of 5-HT
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Structure activity relationships of 5-HT
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs purinergiques › Récepteurs purinergiques P1 › Structure activity relationships of 5-HT
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs sérotoninergiques › Récepteurs de la sérotonine de type 5-HT2 › Récepteur de la sérotonine de type 5-HT2B › Structure activity relationships of 5-HT